cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2022-37-4-180-187cardiotomsk-1636Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESИнгаляционная терапия коморбидного пациента с COVID-19 высокими дозами оксида азота: клинический случайInhalation therapy with high doses of nitric oxide in a comorbid patient with COVID-19: A clinical casehttps://orcid.org/0000-0003-4289-4439КаменщиковН. О.KamenshchikovN. O.

Каменщиков Николай Олегович, канд. мед. наук, врач анестезиолог-реаниматолог, отделение анестезиологии и реанимации, отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Nikolay O. Kamenshchikov, Cand. Sci. (Med.), Intensive Care Physician, Department of Anesthesiology and Intensive Care

111a, Kievskaya str., Tomsk, 634012

nikolajkamenof@mail.ruhttps://orcid.org/0000-0002-1975-043XКузнецовМ. С.KuznetsovM. S.

Кузнецов Михаил Сергеевич, канд. мед. наук, старший научный сотрудник, отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Mikhail S. Kuznetsov, Cand. Sci. (Med.), Senior Research Scientist, Department of Cardiovascular Surgery

111a, Kievskaya str., Tomsk, 634012

kms@cardio-tomsk.ruhttps://orcid.org/0000-0001-9353-7234ДьяковаМ. Л.DiakovaM. L.

Дьякова Мария Леонидовна, канд. мед. наук, научный сотрудник, отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Maria L. Diakova, Cand. Sci. (Med.), Research Scientist, Department of Cardiovascular Surgery

111a, Kievskaya str., Tomsk, 634012

prima.maria@mail.ruhttps://orcid.org/0000-0002-8939-2340ПодоксеновЮ. К.PodoksenovYu. K.

Подоксенов Юрий Кириллович, д-р мед. наук, ведущий научный сотрудник, отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Yury K. Podoksenov, Dr. Sci. (Med.), Leading Research Scientist, Department of Cardiovascular Surgery

111a, Kievskaya str., Tomsk, 634012

uk@cardio-tomsk.ruhttps://orcid.org/0000-0003-2078-4490КалашниковаТ. П.KalashnikovaT. P.

Калашникова Татьяна Петровна, канд. мед. наук, врач клинический фармаколог

634012, Томск, ул. Киевская, 111а

Tatiana P. Kalashnikova, Cand. Sci. (Med.), Clinical Pharmacologist

111a, Kievskaya str., Tomsk, 634012

uk@cardio-tomsk.ruhttps://orcid.org/0000-0003-2672-6136ТёМ. А.TyoM. A.

Тё Марк Артурович, врач ординатор по специальности «анестезиология – реаниматология», отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Mark A. Tyo, Anesthesiology Resident, Department of Anesthesiology and Intensive Care

111a, Kievskaya str., Tomsk, 634012

marik640213@gmail.comhttps://orcid.org/0000-0003-3562-9979ЧурилинаЕ. А.ChurilinaE. A.

Чурилина Елена Александровна, врач анестезиолог-реаниматолог, отделение анестезиологии и реанимации, отделение сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Elena A. Churilina, Intensive Care Physician, Department of Anesthesiology and Intensive Care

111a, Kievskaya str., Tomsk, 634012

lena.semenova.96@inbox.ruhttps://orcid.org/0000-0002-0217-7737КозловБ. Н.KozlovB. N.

Козлов Борис Николаевич, д-р мед. наук, заведующий отделением сердечно-сосудистой хирургии

634012, Томск, ул. Киевская, 111а

Boris N. Kozlov, Dr. Sci. (Med.), Head of Department of Cardiovascular Surgery

111a, Kievskaya str., Tomsk, 634012

bnkozlov@yandex.ruНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation202218012023374180187Copyright © Каменщиков Н.О., Кузнецов М.С., Дьякова М.Л., Подоксенов Ю.К., Калашникова Т.П., Тё М.А., Чурилина Е.А., Козлов Б.Н., 20232023Каменщиков Н.О., Кузнецов М.С., Дьякова М.Л., Подоксенов Ю.К., Калашникова Т.П., Тё М.А., Чурилина Е.А., Козлов Б.Н.Kamenshchikov N.O., Kuznetsov M.S., Diakova M.L., Podoksenov Y.K., Kalashnikova T.P., Tyo M.A., Churilina E.A., Kozlov B.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1636

В статье описан клинический случай терапии коморбидной пациентки с тяжелым течением COVID-19 с использованием ингаляционной терапии высокими дозами оксида азота (NO). Воздушный поток, содержащий NO, был генерирован при помощи аппарата «ПЛАЗОН». Данная терапия проводилась в качестве жизнеспасающей в связи с отсутствием эффекта от лечения, проводимого согласно действующим национальным клиническим рекомендациям по терапии COVID-19. Продемонстрирована безопасность и клиническая эффективность примененной методики.

The article describes a clinical case of inhalation therapy with high doses of nitric oxide (NO) in a comorbid patient with a severe course of COVID-19. An air stream containing NO was generated using the PLAZON device. High-dose NO inhalation therapy was administered as a life-saving option due to the lack of effect from treatment delivered in accordance with the current national clinical guidelines for the treatment of COVID-19. The safety and clinical efficacy of the technique was demonstrated.

терапия оксидом азотаCOVID-19«ПЛАЗОН»коморбидностькардиологияпневмонияNitric oxide therapyCOVID-19PLAZONcomorbiditycardiologypneumoniaReferencesIchinose F., Roberts J.D. Jr., Zapol W.M. Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potential. Circulation. 2004;109(25):3106–3111. DOI: 10.1161/01.CIR.0000134595.80170.62.Ichinose F., Roberts J.D. Jr., Zapol W.M. Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potential. Circulation. 2004;109(25):3106–3111. DOI: 10.1161/01.CIR.0000134595.80170.62.Mehta D.R., Ashkar A.A., Mossman K.L. The Nitric Oxide Pathway Provides Innate Antiviral Protection in Conjunction with the Type I Interferon Pathway in Fibroblasts. PLoS One. 2012;7(2):e31688. DOI: 10.1371/journal.pone.0031688.Mehta D.R., Ashkar A.A., Mossman K.L. The Nitric Oxide Pathway Provides Innate Antiviral Protection in Conjunction with the Type I Interferon Pathway in Fibroblasts. PLoS One. 2012;7(2):e31688. DOI: 10.1371/journal.pone.0031688.Åkerström S., Gunalan V., Keng C.T., Tan Y.-J., Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1–9. DOI: 10.1016/j.virol.2009.09.007.Åkerström S., Gunalan V., Keng C.T., Tan Y.-J., Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1–9. DOI: 10.1016/j.virol.2009.09.007.Xu W., Zheng S., Dweik R.A., Erzurum S.C. Role of epithelial nitric oxide in airway viral infection. Free Radic. Biol. Med. 2006;41(1):19–28. DOI: 10.1016/j.freeradbiomed.2006.01.037.Xu W., Zheng S., Dweik R.A., Erzurum S.C. Role of epithelial nitric oxide in airway viral infection. Free Radic. Biol. Med. 2006;41(1):19–28. DOI: 10.1016/j.freeradbiomed.2006.01.037.Klingstrom J., Åkerström S., Hardestam J., Stoltz M., Simon M., Falk K.I. et al. Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions. Eur. J. Immunol. 2006;36(10):2649–2657. DOI: 10.1002/eji.200535587.Klingstrom J., Åkerström S., Hardestam J., Stoltz M., Simon M., Falk K.I. et al. Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions. Eur. J. Immunol. 2006;36(10):2649–2657. DOI: 10.1002/eji.200535587.Jung K., Gurnani A., Renukaradhya G.J., Saif L.J. Nitric oxide is elicited and inhibits viral replication in pigs infected with porcine respiratory coronavirus but not porcine reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol. 2010;136(3-4):335–339. DOI: 10.1016/j.vetimm.2010.03.022.Jung K., Gurnani A., Renukaradhya G.J., Saif L.J. Nitric oxide is elicited and inhibits viral replication in pigs infected with porcine respiratory coronavirus but not porcine reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol. 2010;136(3-4):335–339. DOI: 10.1016/j.vetimm.2010.03.022.Uehara E.U., de Stefano Shida B., de Brito C.A. The role of nitric oxide in immune responses against viruses is beyond microbicidal activity. Inflamm. Res. 2015;64(11):845–852. DOI: 10.1007/s00011-015-0857-2.Uehara E.U., de Stefano Shida B., de Brito C.A. The role of nitric oxide in immune responses against viruses is beyond microbicidal activity. Inflamm. Res. 2015;64(11):845–852. DOI: 10.1007/s00011-015-0857-2.Vanin A.F. Dinitrosyl iron complexes with thiolate ligands: Physico-chemistry, biochemistry and physiology. Nitric. Oxide. 2009;21(1):1–13. DOI: 10.1016/j.niox.2009.03.005.Vanin A.F. Dinitrosyl iron complexes with thiolate ligands: Physico-chemistry, biochemistry and physiology. Nitric. Oxide. 2009;21(1):1–13. DOI: 10.1016/j.niox.2009.03.005.Vanin A.F. Dinitrosyl Iron сomplexes as a “working form” of nitric oxide in living organisms. Cambridge, UK: Cambridge Scholars Publ.; 2019:276.Vanin A.F. Dinitrosyl Iron сomplexes as a “working form” of nitric oxide in living organisms. Cambridge, UK: Cambridge Scholars Publ.; 2019:276.Vanin A.F. Dinitrosyl iron complexes with thiol-containing ligands can suppress viral infections as donors of the nitrosonium cation (hypothesis). Biophysics (Oxf.). 2020;65(4):698–702. DOI: 10.1134/ S0006350920040260.Vanin A.F. Dinitrosyl iron complexes with thiol-containing ligands can suppress viral infections as donors of the nitrosonium cation (hypothesis). Biophysics (Oxf.). 2020;65(4):698–702. DOI: 10.1134/ S0006350920040260.Deppisch C., Herrmann G., Graepler-Mainka U., Wirtz H., Heyder S., Engel C. et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: A phase I clinical study. Infection. 2016;44(4):513–520. DOI: 10.1007/s15010-0160879-x.Deppisch C., Herrmann G., Graepler-Mainka U., Wirtz H., Heyder S., Engel C. et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: A phase I clinical study. Infection. 2016;44(4):513–520. DOI: 10.1007/s15010-0160879-x.Miller C., McMullin B., Ghaffari A., Stenzler A., Pick N., Roscoe D. et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric. Oxide. 2009;20(1):16–23. DOI: 10.1016/j.niox.2008.08.002.Miller C., McMullin B., Ghaffari A., Stenzler A., Pick N., Roscoe D. et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric. Oxide. 2009;20(1):16–23. DOI: 10.1016/j.niox.2008.08.002.Ma L., Wang W., Le Grange J.M., Wang X., Du S. Li C. et al. Coinfection of SARS-CoV-2 and other respiratory pathogens. Infect. Drug Resist. 2020;13:3045–3053. DOI: 10.2147/IDR.S267238.Ma L., Wang W., Le Grange J.M., Wang X., Du S. Li C. et al. Coinfection of SARS-CoV-2 and other respiratory pathogens. Infect. Drug Resist. 2020;13:3045–3053. DOI: 10.2147/IDR.S267238.Kim D., Quinn J., Pinsky B., Shah N.H., Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085–2086. DOI: 10.1001/jama.2020.6266.Kim D., Quinn J., Pinsky B., Shah N.H., Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085–2086. DOI: 10.1001/jama.2020.6266.Kobayashi J., Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann. Intensiv. Care. 2020;10(1):61. DOI: 10.1186/s13613-020-00681-9.Kobayashi J., Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann. Intensiv. Care. 2020;10(1):61. DOI: 10.1186/s13613-020-00681-9.Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022;10(2):369. DOI: 10.3390/biomedicines10020369.Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022;10(2):369. DOI: 10.3390/biomedicines10020369.Kamenshchikov N.O., Kozlov B.N., Dish A.Y., Podoksenov Y.K., Anfinogenova N.D., Boshchenko A.A. et al. Abstract 11986: A Safety Study of Intermittent versus Continuous Inhaled NO Therapy in Spontaneously Breathing COVID-19 Patients: A Randomized Controlled Trial. Circulation. 2021;144(1):A11986.Kamenshchikov N.O., Kozlov B.N., Dish A.Y., Podoksenov Y.K., Anfinogenova N.D., Boshchenko A.A. et al. Abstract 11986: A Safety Study of Intermittent versus Continuous Inhaled NO Therapy in Spontaneously Breathing COVID-19 Patients: A Randomized Controlled Trial. Circulation. 2021;144(1):A11986.McMahon T.J., Doctor A. Extrapulmonary effects of inhaled nitric oxide: Role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc. Am. Thorac. Soc. 2006;3(2):153–160. DOI: 10.1513/pats.200507-066BG.McMahon T.J., Doctor A. Extrapulmonary effects of inhaled nitric oxide: Role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc. Am. Thorac. Soc. 2006;3(2):153–160. DOI: 10.1513/pats.200507-066BG.

The authors declare that there are no conflicts of interest present.